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Introduction
Low-density lipoprotein cholesterol (LDL-C) is an important 
modifiable risk factor for cardiovascular disease (CVD). LDL-C is 
recognized as the primary target of therapy in clinical practice 
guidelines including in the United States, Europe, and Korea.1-3) 
LDL-C is the most appropriate factor for patient classification 
in risk management of CVD, highlighting the comprehensive 
understanding of the need for accurate and precise LDL-C 
estimation. The accepted gold standard or reference method for 
LDL-C estimation is β-quantification after ultracentrifugation,4) 
which is not commonly affordable as it is labor-intensive, time-
consuming, and expensive.5) Recently, direct homogeneous assays 
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for measurement of LDL-C have been developed and have shown 
reasonable accuracy and precision when compared with the 
reference method.6)
Several formulas have been developed to estimate LDL-C.5)7-11) Of 
these, the most generally used formula worldwide to calculate LDL-C 
is the Friedewald formula and it is accepted as an accurate and cost-
effective alternative to direct measurement.9) However, it cannot 
be applied when the fasting serum triglyceride (TG) concentrations 
are above 400 mg/dL, due to the underestimation and lack of 
concordance with the direct measurement of LDL-C. Since Scharnagl 
et al. first reported the underestimation of the Friedewald formula,12) 
a number of other studies have described the underestimation and 
inaccuracy of the Friedewald formula, especially in extreme lipid 
values and with comorbidities.7)8)12-17) Most alternative formulas 
have been developed using multivariate linear regression analysis 
with LDL-C as a dependent variable and total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C), and TG as independent 
variables.7-11)18) Unlike the other formulas, the Anandaraja formula 
was developed in order to calculate LDL-C without using HDL-C 
as an independent variable.5) However, all of these LDL-C formulas 
have had varying results in different populations or have performed 
more poorly than the Friedewald formula. Although such various 
LDL-C formulas have been developed, only a small number of studies 
have compared them.13-17) LDL-C can be measured to identify high-
risk individuals in the mass screening, as well as to assess an 
individual’s cardiovascular risk among known high risk patients.1-4)19) 
However, previous studies have not separately compared the 
accuracy of calculated LDL-C in both the general population and 
in high-risk patients of CVD. Therefore, in this study, we assessed 
the performance of six LDL-C formulas (Friedewald, de Cordova, 
Vujovic, Chen, Hattori, and Anandaraja) by comparing them with 
the direct measurement of LDL-C in the general population from 
the community-based group and the high-risk patients of CVD 
from the hospital-based group.
Subjects and Methods
Study population
Data for the present study were derived from the Cardiovascular 
and Metabolic Disease Etiology Research Center (CMERC) study, 
an ongoing prospective cohort study. The CMERC study consists 
of the community-based group from the general population and 
the hospital-based group from the patients at high risk of CVD. As 
shown in Fig. 1, initially 2163 participants were enrolled into this 
study. However, to calculate LDL-C using the formulas, we limited our 
main analysis to participants whose TC, TG, HDL-C, and LDL-C were 
all measured and whose TG concentrations were 400 mg/dL or less. 
After excluding a total of 665 participants (596 participants with 
unmeasured directly-measured LDL-C, 45 participant with missing 
Fig. 1. Flow chart of study participants. LDL-C: low-density lipoprotein cholesterol, TG: triglycerides.
Enrolled study participants, n=2163
867 men and 1296 women
・Community-based group, n=1663
・Hospital-based group, n=500
·Community-based group, n=1663
(General population)
590 men and 1073 women
Included study participants, n=447
245 men and 202 women
Final study participants, n=1498
654 men and 844 women
・Community-based group, n=1051
・Hospital-based group, n=447
Included study participants, n=1051
409 men and 642 women
                                                   Excluded particpants, n=612
- Unmeasured directly-measured LDL-C, n=596
- Missing values of serum lipids, n=1
- TG>400 mg/dL, n=15
                                                 Excluded participants, n=53
- Missing values of serum lipids, n=44
- TG>400 mg/dL, n=9
·Hospital-based group, n=500
   (Cardiovascular disease patients)
277 men and 223 women
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value of serum lipids, and 24 participants with TG concentration 
more than 400 mg/dL), a current cross-sectional analysis was 
conducted for a total of 1498 participants who were recruited 
from either the community-based group (n=1051) or the hospital-
based group (n=447). In addition, a sensitivity analysis including 24 
additional people with TG concentration more than 400 mg/dL, was 
also conducted. The community-based group included a free-living 
general population residing in four districts throughout South 
Korea (Seoul, Goyang, Gimpo, and Incheon). Eligibility criteria for 
each inclusion participant comprised of being in the age range of 
30 to 64 years, having lived more than eight months of the year at 
their current residence with no migration plans over the next two 
years, and ability to provide verbal or written consent to participate 
in the study. Participants were excluded if they were diagnosed 
with cancer within the last two years or were currently being 
treated for cancer, had a history of myocardial infarction, stroke, 
or heart failure, were currently involved in pharmaceutical trials, 
and were currently pregnant or reported the possibility of being 
pregnant on the day of registration. The hospital-based group was 
recruited from the cardiology outpatient department at Severance 
hospital, Yonsei University. This study group was registered with 
ClinicalTrials.gov under the identifier number NCT02003781 (www.
clinicaltirals.gov). The hospital-based group included patients 
having conditions known for significantly increased risks of CVD: 
hypertension with subclinical target organ damage, type 2 diabetes 
with microalbuminuria, chronic kidney disease with dialysis or 
transplant, rheumatoid arthritis and on medication, subclinical 
peripheral vascular disease, atrial fibrillation, and immediate family 
members who were myocardial infarction patients. All participants 
provided written informed consent, and the Institutional Review 
Board of Severance Hospital, Yonsei University College of Medicine, 
approved the study protocol.
 
Measurements
Fasting blood samples were collected from the antecubital vein 
after fasting for at least 8 hours. For the community-based group, 
blood samples were sent to an independent research laboratory 
center for analysis. Serum concentrations of TC, TG, HDL-C, and 
LDL-C were measured using enzymatic methods with an automatic 
analyzer (ADVIA 1800, Siemens, Tarrytown, NY, USA). The coefficients 
of variation were 0.5-0.8% for TC, 2.0-2.6% for HDL-C, 2.8-2.9% for 
LDL-C, and 0.9-2.4% for TG. In the hospital-based group, serum 
concentrations of TC, HDL-C, LDL-C, and TG were measured using 
enzymatic methods with an automatic analyzer (Hitachi 7600 
DDP, Hitachi High-Technologies, Tokyo, Japan). The coefficients of 
variation were 0.8-0.9% for TC, 18.3-18.4% for HDL-C, 1.0-1.2% for 
LDL-C, and 1.0-1.2% for TG.
In addition to direct measurement, LDL-C was calculated according 
to the following formulas: 
• Friedewald9): LDL-C=TC-HDL-C-(TG/5)
• Hattori10): LDL-C=(0.94×TC)-(0.94×HDL-C)-(0.19×TG)
• Anandaraja5): LDL-C=(0.9×TC)-(0.9×TG/5)-28
• Vujovic11): LDL-C=TC-HDL-C-(TG/6.58)
• Chen7): LDL-C=(TC-HDL-C)×0.9-(TG×0.1)
• de Cordova8): LDL-C=0.7516×(TC-HDL-C)
Statistical analysis
We performed statistical analyses for all participants and for 
each of the two groups. In addition, participants were classified 
into four groups according to serum TG concentration as follows: 
<100, 100-199, 200-299, and ≥300 mg/dL. In addition, sensitivity 
analysis was carried out when the serum TG concentration was 
more than 400 mg/dL. The performance of all estimated formulas 
was compared at different concentrations of TG. To test for a normal 
distribution, the Q-Q plot (as shown in Supplementary Fig. 1, 2, and 
3), Kolmogorov-Smirnov with the Lilliefors significance correction, 
skewness, and kurtosis were used. The distribution of continuous 
variables were described as means with standard deviations (for 
normally distributed variables) or as a median with an interquartile 
range (for skewed variables) and compared using an independent 
t-test and Wilcoxon rank sum test, respectively. Categorical 
variables are reported as observed numbers and percentages; these 
were compared using the chi-square test. Correlation between 
LDL-C by estimated formulas and by direct measurement was 
calculated using the Pearson’s correlation. The intraclass correlation 
coefficient (ICC) analysis was performed in order to evaluate the 
degree of absolute agreement between the estimated and directly 
measured LDL-C. For the purpose of multiple subdivision analyses, 
ICC for all of serum TG ranges had a 95% confidence interval (CI); 
ICC for each partial TG ranges had 98.75% CI. In addition, we 
compared the performance of ICC only for all of the serum TG 
ranges divided into a community-based group and a hospital-
based group since the correction of multiple comparisons. We also 
used the graphical procedure outlined by Bland-Altman plots and 
Passing & Bablok regression equation. Agreement between the two 
measurements was tested by calculating systematic errors (bias), 
and 95% limits of agreement (LOA) as bias±2 standard deviations as 
described by Bland-Altman plots.20) The percentage error is derived 
by dividing the limits of agreement by the mean value of the 
measurements obtained with the established method.21) Passing 
and Bablok regression analyses are statistical procedures that allow 
valuable estimations of analytical method agreements and possible 
systematic bias, expressed in the equation by y=a+bx, where a is 
the intercept of the line (representing the constant error) and b is 
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the slope in the y axis (representing the proportional error).22)23) If 0 
is not in the 95% CI of the intercept there is a constant difference 
and if 1 is not in the 95% CI of the slope then there is a proportional 
difference between the two methods.23) In addition, the Cusum test 
for linearity was used to evaluate how well a linear model fits the 
data in the Passing and Bablok methods.
All statistical analyses were performed using SAS software 
(version 9.2, SAS, Cary, NC, USA), SPSS software (version 23, IBM 
SPSS Inc., Chicago, IL, USA), and MedCalc software (version 15.4, 
MedCalc, Ostend, Belgium). Statistical significance was defined as a 
two-sided p-value of less than 0.05.
results
The general characteristics of the participants are presented in 
Table 1. A total of 1498 lipid profiles were identified, of which 654 
(43.7%) were male and 844 (56.3%) were female. The median age of 
the participants was 53 years, and the community-based group was 
found to be younger than the hospital-based group. TC ranged from 
93.0 to 337.0 mg/dL with a mean of 189.2 mg/dL; TG ranged from 
16.0 to 392.0 mg/dL with a median of 104.0 mg/dL; HDL-C ranged 
from 17.0 to 124.0 mg/dL with a median of 53.0 mg/dL; and directly-
measured LDL-C ranged from 33.0 to 246.0 mg/dL with a mean 
of 110.7 mg/dL. Of the various formulas, the De Cordova formula 
produced the lowest mean (103.4 mg/dL), and the Anandaraja 
formula produced the highest mean (101.0 mg/dL). The mean values 
of LDL-C were significantly higher in the community-based group 
than in the hospital-based group, likely due to the difference in the 
frequency of lipid-lowering drugs (8.8% and 54.8%, respectively). 
The prevalence of known chronic disorders and medications for 
these diseases were higher in the hospital-based group than in the 
Table 1. General characteristics of study participants (n=1498)
Variables Total (n=1498)
Population-based cohort 
(n=1051)
Hospital-based cohort 
(n=447) p
Age, years 53.0 [41.0-60.0] 50.0 [37.0-56.0] 61.0 [53.0-68.0] <0.001
Sex, n(%)
   Men 654 (43.7) 409 (38.9) 245 (54.8) <0.001
   Women 844 (56.3) 642 (61.1) 202 (45.2) <0.001
Body mass index, kg/m² 24.1±3.4 23.6±3.2 25.4±3.6 <0.001
Total cholesterol, mg/dL 189.2±35.2 195.8±34.3 173.7±32.4 <0.001
Triglycerides, mg/dL 104.0 [76.0-149.0] 101.0 [74.0-145.0] 111.0 [80.0-163.0] 0.004 
HDL-C, mg/dL 53.0 [44.0-62.0] 55.0 [47.0-66.0] 48.0 [41.0-56.0] <0.001
LDL-C, mg/dL
   Directly-measured, mg/dL 110.7±31.3 116.4±30.6 97.5±28.9 <0.001
   Friedewald, mg/dL 110.3±31.0 115.0±30.4 99.0±29.4 <0.001
   Chen, mg/dL 108.9±28.3 113.0 ± 28.0 99.3±26.7 <0.001
   Vujovic, mg/dL 116.1±31.1 120.7±30.6 105.1±29.4 <0.001
   Hattori, mg/dL 103.4±29.1 107.9±28.5 92.8±27.7 <0.001
   De Cordova, mg/dL 101.0±25.1 104.2±25.0 93.5±23.7 <0.001
   Anandaraja, mg/dL 120.6±31.6 127.0±30.5 105.5±29.2 <0.001
Previously known diseases, n(%)
   Hypertension 487 (32.5) 142 (13.5) 345 (77.2) <0.001
   Diabetes mellitus 148 (9.9) 39 (3.7) 109 (24.4) <0.001
   Dyslipidemia 313 (20.9) 156 (14.8) 157 (35.1) <0.001
Medication history, n(%)
   Antihypertensive drug 474 (31.6) 128 (12.2) 346 (77.4) <0.001
   Antidiabetic drug 128 (8.5) 35 (3.3) 93 (20.8) <0.001
   Lipid lowering drug 337 (22.5) 92 (8.8) 245 (54.8) <0.001
Data expressed as a mean±standard deviation for normal distribution, median [interquartile range] for non-normal distribution, or number (percent) for 
categorical variables. HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol
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community-based group. 
Table 2 compared estimated LDL-C using the six formulas to 
directly measured LDL-C according to TG concentration. Along 
with the increase of TG concentration, the difference between 
calculated LDL-C and measured LDL-C also increased. As a 
further visual cue, Supplementary Fig. 4 shows the correlation of 
directly-measured LDL-C with estimated LDL-C. The ICC between 
the estimated and directly-measured LDL-C was significantly 
higher with the Friedewald formula (ICC=0.977; 95% CI: 0.974–
0.979) for all serum TG ranges compared with the Chen formula 
(ICC=0.973; 95% CI: 0.969–0.977; p-value 0.008), the Vujovic 
formula (ICC=0.972; 95% CI: 0.934–0.985; p-value<0.001), the 
Hattori formula (ICC=0.961; 95% CI: 0.849–0.983; p-value< 
0.001), the de Cordova formula (ICC=0.916; 95% CI: 0.734–0.960; 
p-value<0.001), and the Anandaraja formula (ICC=0.901; 95% CI: 
0.787–0.943; p-value<0.001). At the low end of the TG range, the 
Friedewald formula seemed to have better accuracy with an ICC of 
0.980 (98.75% CI=0.974–0.984). At the high end of the TG range, 
the Vujovic formula showed higher accuracy with an ICC of 0.876 
(98.75% CI=0.668–0.951) compared with other formulas. However, 
as shown in Supplementary Fig. 5, the accuracy of the formulas 
have declined as the serum TG concentration increases. 
We also performed the comparison analysis separately for both 
the community-based group and the hospital-based group in 
Table 3, and the results were quite consistent. At all of the TG 
ranges, the Friedewald formula had a significantly higher accuracy 
with an ICC of 0.976 (95% CI 0.973–0.979) compared with the 
Hattori formula (ICC=0.955; 95% CI: 0.754–0.982; p-value<0.001), 
the de Cordova formula (ICC=0.904; 95% CI: 0.488–0.963; 
p-value<0.001) and the Anandaraja formula (ICC=0.888; 95% CI: 
0.741–0.939; p-value<0.001) in the community-based group and 
with an ICC of 0.973 (95% CI 0.967–0.978) compared with the 
Vujovic formula (ICC=0.959; 95% CI: 0.812–0.983; p-value<0.001), 
the de Cordova formula (ICC=0.932; 95% CI: 0.908–0.948; 
p-value<0.001), and the Anandaraja formula (ICC=0.898; 95% 
CI: 0.817–0.936; p-value<0.001) in the hospital-based group, 
respectively. At the low end of the TG ranges, the Friedewald 
formula showed a relatively higher accuracy with an ICC of 0.985 
(98.75% CI=0.981–0.988) in the community-based group, while 
the Chen formula showed a higher accuracy with an ICC of 0.962 
(98.75% CI=0.945–0.974) in the hospital-based group. At the high 
end of the TG ranges, the Vujovic formula showed better accuracy 
with an ICC of 0.893 (98.75% CI=0.677–0.965) in the community-
based group, and the Anandaraja formula had better accuracy 
with an ICC of 0.927 (98.75% CI=0.604–0.987) in the hospital-
based group. An additional comparison analysis was conducted 
as a sensitivity analysis to assess the effect of including 24 
participants with TG concentrations is more than 400 mg/dL shown 
in Supplementary Table 1. The Vujovic formula seemed to have a 
higher accuracy in both the community-based group and the 
hospital-based group with an ICC of 0.569 (95% CI -0.276–0.855) 
and 0.873 (95% CI 0.460–0.971) compared with other formulas, 
respectively. However, as shown in Supplementary Table 2, all of 
the estimated formulas became inaccurate, especially when the TG 
concentrations exceeded 1000 mg/dL. 
Fig. 2 presents the mean differences of the estimated formulas 
against directly measured LDL-C in the Bland-Altman plots in 
the overall population. The mean difference (measured LDL-C – 
estimated LDL-C) represents the estimation of bias between the 
two observations. The mean bias was the lowest for the Friedewald 
formula (0.5 mg/dL, limits of agreement -17.8 and 18.8), followed by 
the Chen formula (1.8 mg/dL, limits of agreement -16.6 and 20.3), 
the Vujovic formula (-5.3 mg/dL, limits of agreement -22.8 and 12.2), 
the Hattori formula (7.3 mg/dL, limits of agreement -11.0 and 25.7), 
the De Cordova formula (9.7 mg/dL, limits of agreement -15.9 and 
35.3), and the Anandaraja formula (–9.8 mg/dL, limits of agreement 
-42.6 and 23.0). The percentage error was the lowest for the Vujovic 
formula (30.2%), followed by the Friedewald formula (33.2%), 
the Chen formula (33.9%), Hattori formula (35.5%), De Cordova 
formula (50.7%), and lastly the Anandaraja formula (54.4%). Fig. 3 
showed the reliability of different methods for measuring LDL-C 
using the Passing & Bablok linear regression analysis. As shown in 
Supplementary Table 3, calculation of the slope and the intercept 
in each formula against for directly measured LDL-C shows that 
the Friedewald formula indicated good agreement without both 
constant and proportional bias.
discussion
Since the release of the first the National Cholesterol Education 
Program Adult Treatment Panel guidelines in 1988, LDL-C has 
been focused on therapeutic decision-making and the efficacy of 
medical intervention.19) It is essential to accurately estimate LDL-C, 
as it has significant implications on cardiovascular risk stratification 
and can affect therapy and outcomes.14) Over the last 40 years, 
the Friedewald formula has been used the most widely to estimate 
LDL-C in clinical practice as well as in health screenings. To improve 
its accuracy and reliability, several modified formulas have been 
suggested. However, these modifications were not found to be 
suitable replacements of the Friedewald formula.
In the present study, we compared Friedewald formula (developed 
in 1972) and other five relatively new formulas (developed in 1998-
2013) against directly measured LDL-C in a Korean population. 
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Table 2. Comparison of estimated formulas to directly-measured LDL-C according to serum TG concentration (TG ≤400 mg/dL)
LDL-C measurement Mean±SD (mg/dL) Mean difference ICC (confidence interval)*
All TG ranges (n=1498)
Directly-measured 110.7±31.3 NA 1.000
Friedewald 110.3±31.0 0.5 0.977 (0.974-0.979)
Chen 108.9±28.3 1.8 0.973 (0.969-0.977)
Vujovic 116.1±31.1 -5.3 0.972 (0.934-0.985)
Hattori 103.4±29.1 7.3 0.961 (0.849-0.983)
De Cordova 101.0±25.1 9.7 0.916 (0.734-0.960)
Anandaraja 120.6±31.6 -9.8 0.901 (0.787-0.943)
TG<100 mg/dL (n=697)  
Directly-measured 106.0±29.5 NA 1.000
Friedewald 107.7±29.4 -1.7 0.980 (0.974-0.984) 
Chen 102.7±26.7 3.3 0.975 (0.957-0.984)
Vujovic 111.1±29.5 -5.2 0.973 (0.903-0.988)
Hattori 101.1±27.6 4.9 0.972 (0.910-0.987)
De Cordova 91.8±22.7 14.1 0.896 (-0.268-0.976)
Anandaraja 123.4±30.1 -17.5 0.843 (-0.129-0.953)
TG 100-199 mg/dL (n=623)
Directly-measured 116.5±32.5 NA 1.000
Friedewald 115.0±32.4 1.4 0.981 (0.976-0.985)
Chen 114.5±29.1 2.0 0.976 (0.969-0.981)
Vujovic 121.6±32.4 -5.1 0.975 (0.922-0.988)
Hattori 107.9±30.4 8.6 0.960 (0.638-0.988)
De Cordova 107.0±24.5 9.4 0.930 (0.641-0.974)
Anandaraja 121.6±32.6 -5.1 0.946 (0.912-0.965)
TG 200-299 mg/dL (n=145)
Directly-measured 110.0±31.8 NA 1.000
Friedewald 105.2±30.1 4.8 0.957 (0.915-0.976)
Chen 113.3±26.8 -3.3 0.952 (0.923-0.970)
Vujovic 116.4±29.9 -6.4 0.952 (0.869-0.977)
Hattori 98.4±28.3 11.6 0.925 (0.278-0.979)
De Cordova 114.1±22.3 -4.1 0.920 (0.870-0.949)
Anandaraja 107.6±30.2 2.4 0.957 (0.933-0.972)
TG 300-399 mg/dL (n=33)
Directly-measured 106.1±27.5 NA 1.000
Friedewald 96.9±27.0 9.2 0.862 (0.575-0.950)
Chen 114.4±24.4 -8.3 0.865 (0.600-0.950)
Vujovic 113.3±27.0 -7.1 0.876 (0.668-0.951)
Hattori 90.4±25.4 15.7 0.809 (-0.071-0.947)
De Cordova 124.0±20.6 -17.9 0.757 (-0.309-0.937)
Anandaraja 97.1±27.9 9.0 0.852 (0.576-0.944)
The mean difference (directly-measured LDL-C – estimated LDL-C) represents the estimation of bias between the two observations. *ICC (95% confidence 
interval) for all TG ranges and ICC (98.75% confidence interval) for each partial TG ranges. LDL-C: low-density lipoprotein cholesterol, TG: triglycerides, SD: 
standard deviation, ICC: intraclass correlation coefficient, NA: not applicable 
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Table 3. Cohort-specific comparison of estimated formulas to directly-measured LDL-C according to serum TG concentration (TG ≤400 mg/dL)　
LDL-C measurement
Community-based group Hospital-based group
Mean±SD (mg/dL) ICC (confidence interval)† Mean±SD ICC (confidence interval)*
All TG ranges (n=1051) (n=447)
Directly-measured 116.4±30.6 1.000 97.5±28.9 1.000
Friedewald 115.0±30.4 0.976 (0.973-0.979) 99.0±29.4 0.973 (0.967-0.978)
Chen 113.0±28.0 0.972 (0.959-0.980) 99.3±26.7 0.970 (0.963-0.976)
Vujovic 120.7±30.6 0.974 (0.952-0.984) 105.1±29.4 0.959 (0.812-0.983)
Hattori 107.9±28.5 0.955 (0.754-0.982) 92.8±27.7 0.966 (0.934-0.980)
De Cordova 104.2±25.0 0.904 (0.488-0.963) 93.5±23.7 0.932 (0.908-0.948)
Anandaraja 127.0±30.5 0.888 (0.741-0.939) 105.5±29.2 0.898 (0.817-0.936)
TG<100 mg/dL (n=513) (n=184)
Directly-measured 110.0±29.3 1.000 94.6±27.3 1.000
Friedewald 110.8±29.3 0.985 (0.981-0.988) 98.9±27.9 0.953 (0.920-0.971)
Chen 105.5±26.7 0.977 (0.919-0.990) 94.9±25.3 0.962 (0.945-0.974)
Vujovic 114.3±29.5 0.980 (0.936-0.991) 102.4±28.0 0.947 (0.684-0.981)
Hattori 104.0±27.5 0.973 (0.790-0.991) 92.8±26.2 0.962 (0.945-0.974)
De Cordova 94.2±22.8 0.885 (-0.270-0.976) 85.3±21.4 0.914 (0.512-0.970)
Anandaraja 128.0±29.7 0.842 (-0.210-0.956) 110.8±27.6 0.805 (0.029-0.933)
TG 100-199 mg/dL (n=422) (n=201)
Directly-measured 123.9±30.8 1.000 100.9±30.3 1.000
Friedewald 121.7±30.9 0.978 (0.968-0.984) 101.1±31.0 0.982 (0.974-0.987)
Chen 120.4±27.8 0.971 (0.953-0.981) 102.1±27.9 0.979 (0.970-0.985)
Vujovic 128.2±30.9 0.973 (0.939-0.986) 107.7±31.0 0.969 (0.767-0.990)
Hattori 114.1±29.1 0.949 (0.442-0.985) 94.7±29.1 0.971 (0.831-0.990)
De Cordova 111.9±23.4 0.909 (0.197-0.973) 96.8±23.5 0.954 (0.918-0.972)
Anandaraja 129.8±30.8 0.932 (0.878-0.958) 104.3±29.6 0.955 (0.930-0.970)
TG 200-299 mg/dL (n=94) (n=51)
Directly-measured 118.6±29.5 1.000 94.2±30.3 1.000
Friedewald 112.3±28.0 0.933 (0.841-0.967) 92.1±29.5 0.983 (0.965-0.992)
Chen 119.7±25.1 0.935 (0.891-0.962) 101.6±26.2 0.963 (0.607-0.990)
Vujovic 123.5± 27.9 0.936 (0.876-0.965) 103.4±29.3 0.962 (0.114-0.992)
Hattori 105.1± 26.3 0.888 (0.036-0.969) 86.1±27.8 0.964 (0.408-0.991)
De Cordova 119.4± 21.0 0.905 (0.840-0.944) 104.5±21.6 0.917 (0.327-0.977)
Anandaraja 115.4±27.5 0.942 (0.900-0.966) 93.2±30.1 0.964 (0.925-0.982)
TG 300-399 mg/dL (n=22) (n=11)
Directly-measured 110.2±30.7 1.000 97.9±17.9 1.000
Friedewald 98.4±29.6 0.859 (0.419-0.959) 93.9±21.8 0.882 (0.395-0.978)
Chen 116.2±26.2 0.886 (-0.652-0.963) 110.9±20.8 0.778 (-0.382-0.964)
Vujovic 115.0±29.3 0.893 (0.677-0.965) 109.7±22.5 0.802 (-0.239-0.967)
Hattori 91.8±27.8 0.805 (-0.213-0.954) 87.6±20.4 0.830 (-0.150-0.972)
De Cordova 125.9±21.6 0.801 (-0.087-0.950) 120.1±18.8 0.600 (-0.337-0.934)
Anandaraja 99.1±30.9 0.835 (0.438-0.949) 93.1±21.5 0.927 (0.604-0.987)
*ICC (95% confidence interval) for all TG ranges and ICC (98.75% confidence interval) for each partial TG ranges. LDL-C: low-density lipoprotein cholesterol, 
TG: triglycerides, SD: standard deviation, ICC: intraclass correlation coefficient, NA: not applicable
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Overall, there were good correlations between estimated LDL-C and 
measured LDL-C. Among the six formulas, the Friedewald formula 
showed the best performance for estimating LDL-C (ICC=0.977; 
95% CI 0.974–0.979), and there was only a small mean difference 
(0.5 mg/dL) compared to the directly-measured LDL-C without both 
a constant and proportional bias. These results showed a similar 
tendency in each of the different groups divided according to 
cardiovascular risk. However, when the serum TG concentrations 
exceeded 400 mg/dL, the Vujovic formula performed well in both 
the community-based group and the hospital-based group.
As in previous studies, of all clinical parameters, serum TG 
concentration was the most significant contributor in determining 
the difference between directly-measured LDL-C and estimated 
LDL-C.24-26) The differences between directly measured LDL-C and 
estimated LDL-C were related to TG concentration, as it was also 
shown in this study that underestimation of LDL-C increased with 
Fig. 2. Bland-Altman plots of estimated formulas against directly-measured LDL-C. The mean difference represents the estimation of bias between the 
two observations and the percentage error represents the proportion between the magnitude of measurement and error in measurement. LDL-C: low-
density lipoprotein cholesterol.
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the concentration of TG.24-26) Results of the study were consistent 
with previous studies, indicating that the Friedewald formula 
performs poorly when TG concentrations are very high.7)8)14)16)17)24)
The present study also had several limitations that need to be 
addressed. First, the β-quantification method was not used, which 
is considered the gold standard method for measuring LDL-C. 
Fig. 3. Passing & Bablok regression of estimated formulas against directly-measured LDL-C. The dotted line represents the line of identity. No significant 
deviation from linearity. LDL-C: low-density lipoprotein cholesterol.
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Instead, LDL-C was measured using the enzymatic method, which 
had an assay precision within the NCEP performance guidelines, 
producing a total error rate of ≤12%, an accuracy rate of ±4%, 
and a CV rate ≤4%.4)27) Second, taking only a single measurement 
of LDL-C may have resulted in misclassification of the participants. 
Despite being commonly used in clinical decision-making, most 
of the guidelines suggested sequential measurements to improve 
the accuracy and precision of LDL-C with intervention. In addition, 
direct comparison was limited, as the lipid measurement methods 
differed between the community-based group and the hospital-
based group. A different method of evaluation of the directly 
measured LDL-C could lead to misclassification of the outcome. 
However, the effects of non-differential misclassification would 
have resulted in a bias toward null. Finally, based on the exclusion 
criteria, a bias in the selection of participants is possible. In addition, 
we did not exclude participants who were taking statins or other 
lipid-modifying agents, which could have affected results. 
In conclusion, most of the LDL-C formulas correlated well 
with directly-measured LDL-C overall, especially at a serum TG 
concentration of <300 mg/dL. Among the six LDL-C formulas, the 
Friedewald formula showed the best performance for estimating 
LDL-C, while the Vujovic formula showed a higher accuracy in 
people with TG ≥300 mg/dL compared with other formulas. 
Results indicated that the Friedewald formula could be used as 
an alternative cost-effective tool to measure LDL-C when a direct 
measurement cannot be afforded or accuracy is not crucial. In 
addition, the Vujovic formula could be used instead of Friedewald 
formula for the estimation of LDL-C in participants with serum 
TG concentrations is greater than 400 mg/dL, which is well 
known as the limitation of Friedewald formula. However, with the 
hypertriglyceridemic samples, the LDL-C calculation obtained from 
LDL-C formulas exhibited the poorer accuracy, which could affect 
clinical decision-making.
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